Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (1246)	7/26/1999 9:49:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1826

Orphan Drug status is given as incentive. In this case, the incentive drove controlled clinical trials to prove that the pilocarpine tablets were effective for the dry mouth indication. Without such data, any physician that would have administered the drug would have done such in a vacuum. Not that any of that has anything to do with current management. BTW, what is Blitzer doing these days? Trying to beat the August doldrums in France?